Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Clinical trial NCT06031558 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06031558
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-31
- Primary completion
- 2025-04-10
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.